TPST

Tempest Therapeutics, Inc.

2.03 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Tempest Therapeutics, Inc. stock is down -37.54% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 11 June’s closed higher than May. 100% of analysts rate it a buy.

About Tempest Therapeutics, Inc.

Tempest Therapeutics Inc. engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors.